Merck Eyes COVID Pill for Ebola Outbreak

Merck is actively discussing with global health authorities the potential repurposing of its COVID-19 antiviral pill, molnupiravir, to treat a rare strain of Ebola. This consideration comes in response to a significant outbreak in the Democratic Republic of Congo. The specific Ebola strain, known as Bundibugyo, has impacted an estimated 1,100 people, resulting in 42 deaths, and currently has no approved vaccines or treatments.

Molnupiravir, developed by Merck and Ridgeback Biotherapeutics, is branded as Lagevrio and was initially approved for emergency use against mild-to-moderate COVID-19 in high-risk adults. While not an approved Ebola treatment, preliminary animal studies suggest molnupiravir may offer efficacy against the virus and could be valuable for preventing infections among those most at risk. The company is also examining its existing Ebola vaccine technology for potential adaptation.